Rallybio Corp Financials
Rallybio Corp (RLYB) reported $858K in revenue for fiscal year 2025, up 34.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Rallybio’s balance sheet shows a cash-funded development model, with liquidity rebuilt by investment runoff rather than by revenue or borrowing.
Between FY2024 and FY2025, net loss improved from-$57.8M to-$9.0M , but operating cash burn only eased from-$49.3M to-$29.8M . That gap means the earnings improvement did not come from a self-funding business; liquidity improved mainly because investing cash inflow reached$47.3M while financing contributed just$16K .
With
The cost base is being actively narrowed: R&D spending fell from
Financial Health Signals
Rallybio Corp does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Rallybio Corp scores 5.00, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($89.2M) relative to total liabilities ($4.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Rallybio Corp passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Rallybio Corp reported a net loss of $9.0M while operations used $29.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Rallybio Corp generated $858K in revenue in fiscal year 2025. This represents an increase of 34.9% from the prior year.
Rallybio Corp's EBITDA was -$33.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 45.4% from the prior year.
Rallybio Corp reported -$9.0M in net income in fiscal year 2025. This represents an increase of 84.5% from the prior year.
Rallybio Corp earned -$1.59 per diluted share (EPS) in fiscal year 2025. This represents an increase of 85.0% from the prior year.
Cash & Balance Sheet
Rallybio Corp held $31.4M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Rallybio Corp's ROE was -15.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 78.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Rallybio Corp invested $19.6M in research and development in fiscal year 2025. This represents a decrease of 52.8% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
RLYB Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Revenue | $646K | $858K+34.9% | $636K | N/A | N/A | N/A | N/A |
| R&D Expenses | $11.4M | $19.6M-52.8% | $41.5M-22.5% | $53.5M+31.6% | $40.7M+51.2% | $26.9M+52.6% | $17.6M |
| SG&A Expenses | $16.9M | $14.3M-27.0% | $19.6M-22.7% | $25.4M-6.6% | $27.2M+45.1% | $18.7M+144.2% | $7.7M |
| Operating Income | -$27.7M | -$33.1M+45.3% | -$60.5M+23.4% | -$78.9M-16.3% | -$67.9M-48.7% | -$45.6M-80.4% | -$25.3M |
| Interest Expense | N/A | N/A | N/A | N/A | $0-100.0% | $10K-79.6% | $49K |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0+100.0% | -$15K |
| Net Income | $45.6M | -$9.0M+84.5% | -$57.8M+22.5% | -$74.6M-11.9% | -$66.7M-41.8% | -$47.0M-77.8% | -$26.4M |
| EPS (Diluted) | — | -$1.59+85.0% | -$10.61 | -$1.84+12.0% | -$2.09-13.6% | -$1.84 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
RLYB Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $62.3M-8.6% | $68.1M-41.1% | $115.6M-35.9% | $180.4M-1.0% | $182.2M+28.4% | $141.9M |
| Current Assets | $61.3M-9.7% | $67.8M-40.9% | $114.8M-36.0% | $179.5M-0.8% | $180.9M+28.0% | $141.3M |
| Cash & Equivalents | $31.4M+125.7% | $13.9M-43.2% | $24.5M-57.0% | $57.0M-67.5% | $175.3M+25.0% | $140.2M |
| Total Liabilities | $4.3M-33.3% | $6.5M-31.6% | $9.4M-15.1% | $11.1M+68.9% | $6.6M+12.4% | $5.9M |
| Current Liabilities | $4.2M-32.3% | $6.2M-32.6% | $9.3M-13.8% | $10.7M+64.0% | $6.6M+12.1% | $5.8M |
| Total Equity | $58.0M-6.0% | $61.7M-41.9% | $106.2M-37.3% | $169.3M-3.6% | $175.6M+29.1% | $136.0M |
| Retained Earnings | -$302.0M-3.1% | -$293.0M-24.6% | -$235.2M-46.4% | -$160.7M-70.9% | -$94.0M-100.0% | -$47.0M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
RLYB Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $26.7M | -$29.8M+39.5% | -$49.3M+18.2% | -$60.3M-5.2% | -$57.3M-25.8% | -$45.5M-106.6% | -$22.0M |
| Capital Expenditures | N/A | N/A | $0-100.0% | $12K-77.8% | $54K-83.8% | $333K+143.1% | $137K |
| Free Cash Flow | N/A | N/A | -$49.3M+18.2% | -$60.3M-5.1% | -$57.3M-25.0% | -$45.9M-106.8% | -$22.2M |
| Investing Cash Flow | $56.6M | $47.3M+41.1% | $33.5M+21.1% | $27.7M+124.7% | -$112.2M-4708.0% | -$2.3M-12.6% | -$2.1M |
| Financing Cash Flow | $140K | $16K-99.7% | $5.2M+3535.7% | $143K-99.7% | $51.1M-38.4% | $83.0M-42.7% | $144.9M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
RLYB Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Margin | -3853.6% | -9512.0% | N/A | N/A | N/A | N/A |
| Net Margin | -1046.4% | -9084.1% | N/A | N/A | N/A | N/A |
| Return on Equity | -15.5%+78.2pp | -93.7%-23.5pp | -70.2%-30.9pp | -39.4%-12.6pp | -26.8%-7.3pp | -19.4% |
| Return on Assets | -14.4%+70.4pp | -84.8%-20.3pp | -64.5%-27.6pp | -36.9%-11.1pp | -25.8%-7.2pp | -18.6% |
| Current Ratio | 14.50+3.6x | 10.87-1.5x | 12.39-4.3x | 16.71-10.9x | 27.61+3.4x | 24.18 |
| Debt-to-Equity | 0.070.0x | 0.100.0x | 0.090.0x | 0.070.0x | 0.040.0x | 0.04 |
| FCF Margin | N/A | -7748.7% | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Rallybio Corp Ranks
Frequently Asked Questions
What is Rallybio Corp's annual revenue?
Rallybio Corp (RLYB) reported $858K in total revenue for fiscal year 2025. This represents a 34.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Rallybio Corp's revenue growing?
Rallybio Corp (RLYB) revenue grew by 34.9% year-over-year, from $636K to $858K in fiscal year 2025.
Is Rallybio Corp profitable?
No, Rallybio Corp (RLYB) reported a net income of -$9.0M in fiscal year 2025.
What is Rallybio Corp's EBITDA?
Rallybio Corp (RLYB) had EBITDA of -$33.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Rallybio Corp's return on equity (ROE)?
Rallybio Corp (RLYB) has a return on equity of -15.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Rallybio Corp's operating cash flow?
Rallybio Corp (RLYB) recorded an outflow of $29.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Rallybio Corp's total assets?
Rallybio Corp (RLYB) had $62.3M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Rallybio Corp spend on research and development?
Rallybio Corp (RLYB) invested $19.6M in research and development during fiscal year 2025.
What is Rallybio Corp's current ratio?
Rallybio Corp (RLYB) had a current ratio of 14.50 as of fiscal year 2025, which is generally considered healthy.
What is Rallybio Corp's debt-to-equity ratio?
Rallybio Corp (RLYB) had a debt-to-equity ratio of 0.07 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Rallybio Corp's return on assets (ROA)?
Rallybio Corp (RLYB) had a return on assets of -14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Rallybio Corp's cash runway?
Based on fiscal year 2025 data, Rallybio Corp (RLYB) had $31.4M in cash against an annual operating cash burn of $29.8M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Rallybio Corp's Altman Z-Score?
Rallybio Corp (RLYB) has an Altman Z-Score of 5.00, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Rallybio Corp's Piotroski F-Score?
Rallybio Corp (RLYB) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Rallybio Corp's earnings high quality?
Rallybio Corp (RLYB) reported a net loss of $9.0M while operations used $29.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.